AU2017220785B2 - Method and system for early risk assessment of preterm delivery outcome - Google Patents
Method and system for early risk assessment of preterm delivery outcome Download PDFInfo
- Publication number
- AU2017220785B2 AU2017220785B2 AU2017220785A AU2017220785A AU2017220785B2 AU 2017220785 B2 AU2017220785 B2 AU 2017220785B2 AU 2017220785 A AU2017220785 A AU 2017220785A AU 2017220785 A AU2017220785 A AU 2017220785A AU 2017220785 B2 AU2017220785 B2 AU 2017220785B2
- Authority
- AU
- Australia
- Prior art keywords
- abundance
- value
- taxonomic
- values
- microbial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 182
- 238000012384 transportation and delivery Methods 0.000 title claims abstract description 166
- 238000012502 risk assessment Methods 0.000 title abstract description 16
- 244000005700 microbiome Species 0.000 claims abstract description 272
- 230000000813 microbial effect Effects 0.000 claims abstract description 195
- 239000000203 mixture Substances 0.000 claims abstract description 92
- 230000035935 pregnancy Effects 0.000 claims abstract description 90
- 238000012512 characterization method Methods 0.000 claims abstract description 54
- 230000001186 cumulative effect Effects 0.000 claims description 50
- 230000003247 decreasing effect Effects 0.000 claims description 49
- 238000012163 sequencing technique Methods 0.000 claims description 45
- 230000001955 cumulated effect Effects 0.000 claims description 39
- 230000015654 memory Effects 0.000 claims description 20
- 230000009466 transformation Effects 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 17
- 230000001413 cellular effect Effects 0.000 claims description 16
- 239000003550 marker Substances 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 238000000684 flow cytometry Methods 0.000 claims description 11
- 238000003384 imaging method Methods 0.000 claims description 11
- 238000001712 DNA sequencing Methods 0.000 claims description 10
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 238000003271 compound fluorescence assay Methods 0.000 claims description 9
- 238000007824 enzymatic assay Methods 0.000 claims description 9
- 230000002255 enzymatic effect Effects 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 238000007400 DNA extraction Methods 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 238000007899 nucleic acid hybridization Methods 0.000 claims description 7
- 238000000386 microscopy Methods 0.000 claims description 6
- 238000007481 next generation sequencing Methods 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001215 vagina Anatomy 0.000 claims description 4
- 210000004381 amniotic fluid Anatomy 0.000 claims description 3
- 210000003756 cervix mucus Anatomy 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 210000004392 genitalia Anatomy 0.000 claims description 3
- 230000003239 periodontal effect Effects 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 3
- 210000000664 rectum Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 238000011426 transformation method Methods 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 195
- 108020004414 DNA Proteins 0.000 description 47
- 239000000047 product Substances 0.000 description 12
- 238000005204 segregation Methods 0.000 description 12
- 208000005107 Premature Birth Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000002790 cross-validation Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 238000000926 separation method Methods 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 208000037009 Vaginitis bacterial Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012854 evaluation process Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
- A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
- A61B5/4343—Pregnancy and labour monitoring, e.g. for labour onset detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Data Mining & Analysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Molecular Biology (AREA)
- Databases & Information Systems (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Software Systems (AREA)
- Bioethics (AREA)
- Evolutionary Computation (AREA)
- Artificial Intelligence (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Microbiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621005426 | 2016-02-16 | ||
| IN201621005426 | 2016-02-16 | ||
| PCT/IB2017/050840 WO2017141169A1 (en) | 2016-02-16 | 2017-02-15 | Method and system for early risk assessment of preterm delivery outcome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017220785A1 AU2017220785A1 (en) | 2018-09-27 |
| AU2017220785B2 true AU2017220785B2 (en) | 2019-02-21 |
Family
ID=59624818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017220785A Active AU2017220785B2 (en) | 2016-02-16 | 2017-02-15 | Method and system for early risk assessment of preterm delivery outcome |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11062808B2 (OSRAM) |
| EP (1) | EP3416653B1 (OSRAM) |
| JP (1) | JP7060518B2 (OSRAM) |
| CN (1) | CN108778287B (OSRAM) |
| AR (1) | AR107737A1 (OSRAM) |
| AU (1) | AU2017220785B2 (OSRAM) |
| WO (1) | WO2017141169A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2699733C1 (ru) * | 2018-03-30 | 2019-09-09 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) | Способ лабораторной ультразвуковой диагностики ранних стадий жеребости |
| EP3620539A1 (en) * | 2018-08-10 | 2020-03-11 | Tata Consultancy Services Limited | Method and system for improving amplicon sequencing based taxonomic resolution of microbial communities |
| GB2612911B (en) * | 2019-02-14 | 2023-11-22 | Mirvie Inc | Methods and systems for determining a pregnancy-related state of a subject |
| CN112587089B (zh) * | 2020-11-19 | 2023-04-21 | 新希望六和股份有限公司 | 基于人工智能的妊娠检测方法、装置、计算机设备和介质 |
| KR20230158101A (ko) * | 2021-03-18 | 2023-11-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 수술 위험도 점수를 생성하는 시스템 및 방법 및 그 용도 |
| KR102559223B1 (ko) * | 2021-07-19 | 2023-07-26 | 주식회사 디앤피바이오텍 | 기계 학습에 기반한 조산 위험도 예측 장치 |
| WO2023023475A1 (en) * | 2021-08-17 | 2023-02-23 | Birth Model, Inc. | Predicting time to vaginal delivery |
| KR20230150145A (ko) | 2022-04-21 | 2023-10-30 | 이화여자대학교 산학협력단 | 마이크로바이옴을 분석하는 학습 모델을 이용한 조산 예측 방법 및 분석장치 |
| CN115227295B (zh) * | 2022-09-19 | 2023-01-24 | 深圳市雄帝科技股份有限公司 | 咽拭子采样设备 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060172330A1 (en) * | 2005-01-14 | 2006-08-03 | Idaho Research Foundation And Procter & Gamble | Categorization of microbial communities |
| US20090299212A1 (en) * | 2006-12-11 | 2009-12-03 | Principe Jose C | System and Method for Analyzing Progress of Labor and Preterm Labor |
| US20110152840A1 (en) * | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| US20120270747A1 (en) * | 2009-10-29 | 2012-10-25 | The Trustees Of The University Of Pennsylvania | Method of predicting risk of pre-term birth |
| US20140186332A1 (en) * | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
| WO2014152985A1 (en) * | 2013-03-14 | 2014-09-25 | Children's Hospital Medical Center | Biomarkers of preterm necrotizing enterocolitis |
| US20140287948A1 (en) * | 2013-03-15 | 2014-09-25 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| WO2015153841A1 (en) * | 2014-04-04 | 2015-10-08 | Ritter Pharmaceuticals, Inc. | Methods and compositions for microbiome alteration |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8068990B2 (en) * | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
| US20110144076A1 (en) * | 2008-05-01 | 2011-06-16 | Michelle A Williams | Preterm delivery diagnostic assay |
| GB2535034A (en) * | 2013-07-21 | 2016-08-10 | Whole Biome Inc | Methods and systems for microbiome characterization, monitoring and treatment |
| US10683557B2 (en) * | 2014-06-30 | 2020-06-16 | The Chinese University Of Hong Kong | Detecting bacterial taxa for predicting adverse pregnancy outcomes |
-
2017
- 2017-02-15 EP EP17752766.0A patent/EP3416653B1/en active Active
- 2017-02-15 CN CN201780018749.0A patent/CN108778287B/zh active Active
- 2017-02-15 WO PCT/IB2017/050840 patent/WO2017141169A1/en not_active Ceased
- 2017-02-15 US US16/076,622 patent/US11062808B2/en active Active
- 2017-02-15 AU AU2017220785A patent/AU2017220785B2/en active Active
- 2017-02-15 JP JP2018551395A patent/JP7060518B2/ja active Active
- 2017-02-16 AR ARP170100387A patent/AR107737A1/es unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060172330A1 (en) * | 2005-01-14 | 2006-08-03 | Idaho Research Foundation And Procter & Gamble | Categorization of microbial communities |
| US20090299212A1 (en) * | 2006-12-11 | 2009-12-03 | Principe Jose C | System and Method for Analyzing Progress of Labor and Preterm Labor |
| US20120270747A1 (en) * | 2009-10-29 | 2012-10-25 | The Trustees Of The University Of Pennsylvania | Method of predicting risk of pre-term birth |
| US20110152840A1 (en) * | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| US20140186332A1 (en) * | 2012-12-28 | 2014-07-03 | NX Pharmagen | Biomarkers of preterm birth |
| WO2014152985A1 (en) * | 2013-03-14 | 2014-09-25 | Children's Hospital Medical Center | Biomarkers of preterm necrotizing enterocolitis |
| US20140287948A1 (en) * | 2013-03-15 | 2014-09-25 | Sera Prognostics, Inc. | Biomarkers and methods for predicting preterm birth |
| WO2015153841A1 (en) * | 2014-04-04 | 2015-10-08 | Ritter Pharmaceuticals, Inc. | Methods and compositions for microbiome alteration |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190046105A1 (en) | 2019-02-14 |
| JP2019511922A (ja) | 2019-05-09 |
| US11062808B2 (en) | 2021-07-13 |
| EP3416653A4 (en) | 2019-06-19 |
| AU2017220785A1 (en) | 2018-09-27 |
| AR107737A1 (es) | 2018-05-30 |
| CN108778287A (zh) | 2018-11-09 |
| EP3416653A1 (en) | 2018-12-26 |
| CN108778287B (zh) | 2021-08-31 |
| JP7060518B2 (ja) | 2022-04-26 |
| EP3416653B1 (en) | 2022-05-25 |
| WO2017141169A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017220785B2 (en) | Method and system for early risk assessment of preterm delivery outcome | |
| Serrano et al. | Racioethnic diversity in the dynamics of the vaginal microbiome during pregnancy | |
| Walther-António et al. | Pregnancy's stronghold on the vaginal microbiome | |
| Drell et al. | Characterization of the vaginal micro-and mycobiome in asymptomatic reproductive-age Estonian women | |
| Haque et al. | First-trimester vaginal microbiome diversity: A potential indicator of preterm delivery risk | |
| Norton et al. | Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18 | |
| Mehta et al. | The vaginal microbiota over an 8-to 10-year period in a cohort of HIV-infected and HIV-uninfected women | |
| Sinha et al. | Quantification of human microbiome stability over 6 months: implications for epidemiologic studies | |
| US20220243247A1 (en) | Vaginal microbiome markers for prediction of prevention of preterm birth and other adverse pregnancy outcomes | |
| EP3023504B1 (en) | Method and device for detecting chromosomal aneuploidy | |
| EP4099335A1 (en) | System and method for estimation of delivery date of pregnant subject using microbiome data | |
| Bybjerg-Grauholm et al. | RNA sequencing of archived neonatal dried blood spots | |
| Levine-Tiefenbrun et al. | Association of COVID-19 RT-qPCR test false-negative rate with patient age, sex and time since diagnosis | |
| CN116779077A (zh) | 基于体检标志物构建生物学年龄及衰老评价的方法及系统 | |
| Benn | Posttest risk calculation following positive noninvasive prenatal screening using cell-free DNA in maternal plasma | |
| Mitnitski | Epigenetic biomarkers for biological age | |
| Valinetz et al. | Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV | |
| Davidson et al. | Methodological approaches in 16S sequencing of female reproductive tract in fertility patients: a review | |
| JP7722702B2 (ja) | 絨毛膜羊膜炎の発症予測方法 | |
| Mussavi Rizi et al. | Modeling trajectories of routine blood tests as dynamic biomarkers for outcome in spinal cord injury | |
| WO2022269566A1 (en) | Systems and methods for determining oral microbiome compositions and health outcomes | |
| Schor et al. | Using machine learning to predict the risk of developing hypertensive disorders of pregnancy using a contemporary nulliparous cohort | |
| Chowdhury et al. | Asymptomatic SARS-CoV-2 infections tend to occur less frequently in developed nations | |
| de Salazar et al. | Sample Pooling as an efficient strategy for SARS-COV-2 RT-PCR screening: a multicenter study in Spain | |
| Mao et al. | Identifying COVID-19 cases in outpatient settings |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |